Barclays PLC Raises Stock Position in Simulations Plus, Inc. (NASDAQ:SLP)

Barclays PLC boosted its position in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 390.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,473 shares of the technology company’s stock after purchasing an additional 22,669 shares during the period. Barclays PLC owned approximately 0.14% of Simulations Plus worth $911,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. First Horizon Advisors Inc. raised its stake in Simulations Plus by 82.6% during the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock worth $26,000 after purchasing an additional 370 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Simulations Plus by 7.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock valued at $311,000 after acquiring an additional 456 shares during the period. Pitcairn Co. raised its stake in shares of Simulations Plus by 9.1% in the 3rd quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock valued at $211,000 after acquiring an additional 549 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of Simulations Plus by 1.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 54,813 shares of the technology company’s stock valued at $2,665,000 after acquiring an additional 784 shares during the period. Finally, nVerses Capital LLC raised its stake in shares of Simulations Plus by 1,100.0% in the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after acquiring an additional 1,100 shares during the period. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Stock Performance

Shares of SLP stock opened at $27.94 on Tuesday. The stock has a market capitalization of $561.17 million, a P/E ratio of 57.02 and a beta of 0.76. The company has a 50 day moving average price of $30.17 and a 200 day moving average price of $34.82. Simulations Plus, Inc. has a fifty-two week low of $27.07 and a fifty-two week high of $51.22.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The firm had revenue of $18.70 million during the quarter, compared to analysts’ expectations of $19.73 million. During the same quarter in the previous year, the business posted $0.18 earnings per share. The business’s quarterly revenue was up 19.9% compared to the same quarter last year. On average, research analysts forecast that Simulations Plus, Inc. will post 1.1 EPS for the current fiscal year.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $31.76, for a total transaction of $635,200.00. Following the completion of the transaction, the director now owns 3,442,584 shares in the company, valued at $109,336,467.84. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 20.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SLP shares. BTIG Research reduced their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. StockNews.com downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, November 6th. Finally, Stephens assumed coverage on shares of Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.